Sun Pharma Advanced Research Company Limited
SPARC · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹381.46. Low-confidence estimate — limited data.
Piotroski F-score 3/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%276.9%
- ✓Low debt (D/E < 0.5)0.42x
- ✕Positive free cash flow
- ✓Revenue growth > 10%6717%
- –Earnings growing
- ✓Net margin ≥ 10%3967.3%
- ✓Current ratio > 1.52.47
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 4.74
- ✕Piotroski ≥ 73/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Strong return on equity (276.9%).
- •Healthy profit margin (3967.3%).
- •Trading near its 52-week high.
- •Financially solid — Altman Z 4.74.
Weaknesses
- •Weak Piotroski score (3/9).
Opportunities
- •Revenue growing (6717% YoY).
- •Trading in our value buy zone versus sector peers.
- •Trades ~100% below our estimated fair value.
About Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosi
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.